Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Rhea-AI Summary

Kura Oncology (NASDAQ: KURA) announced its upcoming participation in the JMP Securities Hematology and Oncology Summit. Troy Wilson, President and Chief Executive Officer, will participate in a virtual fireside chat on December 2, 2024, at 2:00 p.m. ET / 11:00 a.m. PT. The event will be accessible via live audio webcast through the Investors section of Kura's website, with a replay available after the event.

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available following the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contacts

Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com

Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com

FAQ

When is Kura Oncology (KURA) presenting at the JMP Securities Summit 2024?

Kura Oncology will present at the JMP Securities Hematology and Oncology Summit on December 2, 2024, at 2:00 p.m. ET / 11:00 a.m. PT.

How can investors watch Kura Oncology's (KURA) JMP Securities presentation?

Investors can watch the live audio webcast through the Investors section of Kura's website at www.kuraoncology.com. An archived replay will be available after the event.

What type of event will KURA participate in at the JMP Securities Summit?

KURA will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit.